leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 23:20:17 - browse：65852

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： How AI helped researchers track recovery from depression

WSS

Brain 'hot spot' may explain why African Americans feel greater pain

Biotech stock slump in 2023: awaiting the turnaround

Lasker Awards 2023: Winners in biomedical research

How AI helped researchers track recovery from depression

CDC's new outbreak response network to include Northeastern

FDA panel to weigh approval of NurOwn, controversial ALS drug

explore

leisure time

focus

United colonoscopy coverage change 'may cost lives,' doctors say

FDA panel to weigh approval of NurOwn, controversial ALS drug

Medical records are filled with copy

These geoengineering technologies could help combat the climate crisis, scientists say

Peter Hotez and the public health issue of online harassment

Brain 'hot spot' may explain why African Americans feel greater pain

The high cost of giving birth even with insurance

Readout LOUD podcast: possible new ALS drug, artificial wombs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Did the public have the right to know Arthur Ashe had AIDS?

focus

How Vertex's cystic fibrosis drug is changing patients' lives

CDC's new outbreak response network to include Northeastern

Biotech lab space demand falls sharply

Meta looks to target Twitter with a rival app called Threads

STAT Virtual Event: Putting AI to the Test

Drug for rare kidney disease narrowly misses mark in clinical trial

explore

entertainment

leisure time

entertainment